Nivolumab-Induced Exocrine Pancreatic Insufficiency

Immunotherapy is increasingly gaining applicability for several malignancies. While the survival of several malignancies has dramatically improved, immune-related adverse events (irAEs) can occur and can cause severe damage to patients. Side effects such as colitis are well known nowadays; however, with increased use of immunotherapy, less common side effects should also be addressed. In this article, 2 patients that received nivolumab developed exocrine dysfunction of the pancreas. Endocrine dysfunction has been well known, but exocrine dysfunction is less often described. It is important to be aware of this side effect because it is possibly underdiagnosed. Symptoms often mimic symptoms of malignancy, chemotherapy side effects, or immune-related colitis. Although the exact mechanism is yet to be elaborated, dormant CD8+ T cells are likely to be involved. No known therapy is yet been proven to be effective. More knowledge and research about irAEs will lead to possible therapies that will be effective. Currently, high-dose prednisone is recommended based on expert opinion.

Angaben zum Objekt

• Standort: Deutsche Nationalbibliothek Frankfurt am Main
• Umfang: Online-Ressource
• Sprache: Englisch

Verweise und Beziehungen

• Erschienen in: Nivolumab-Induced Exocrine Pancreatic Insufficiency ; volume:14 ; number:3 ; year:2021 ; pages:1627-1631 ; extent:5 ; Case reports in oncology ; 14, Heft 3 (2021), 1627-1631 (gesamt 5)

Beteiligte, Orts- und Zeitangaben

• Urheber: Sweep, Boudewijn ; Wilgenhof, Sofie ; Anten, Sander

Weitere Informationen

• DOI: 10.1159/000519588
• URN: urn:nbn:de:101:1-2022011223391890175608
• Rechteinformation: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
• Letzte Aktualisierung: 15.08.2025, 07:35 MESZ